Stay updated with breaking news from Director Bernd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.56) EPS, […]
Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […]
The Korea Institute of Energy Research(KIER) held a ceremony to sign Memoranda of Understanding (MOUs) in the field of clean energy with Forschungszentrum Jüli
Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Aprea Therapeutics in a research note issued to investors on Tuesday, March 26th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.00) per share for the quarter. Wedbush […]
Aprea Therapeutics (NASDAQ:APRE – Free Report) had its price target boosted by Wedbush from $9.00 to $11.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $20.00 price target on shares of […]